Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraxol weekly oral paclitaxel extension and safety study
ACTRN12615000881538Phase 2Completed
- Sponsor
- Athenex
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of paclitaxel + encequidar, paclitaxel and encequidar in cancer (2 arms), sponsored by Athenex. Primary endpoints: Safety and tolerability by incidence of adverse events, Safety and tolerability by routine laboratory safety tests and 1 more. Started Sep 2015; status: completed.
02
Drugs
paclitaxel + encequidarpaclitaxelencequidar
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12615000881538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000881538.